Ernexa Therapeutics Complies with Nasdaq Listing Requirements

Ernexa Therapeutics has regained compliance with Nasdaq for continued listing, allowing its stock to continue trading on The Nasdaq Stock Market. The company received formal notice on July 1, 2025, stating compliance with Nasdaq’s minimum bid price requirement. Ernexa is focused on advancing programs towards the clinic and plans to initiate its first clinical trial in early 2026. The company’s innovative stem cell therapies, including ERNA-101 and ERNA-102, aim to treat advanced cancer and autoimmune diseases by activating the immune system and targeting inflammation. For more information, visit www.ernexatx.com.

Read more at GlobeNewswire: Ernexa Therapeutics Regains Compliance with Nasdaq Listing